Cefepime
Fourth-Generation Cephalosporins
Sold as Exblifep
- Drug class
- Fourth-Generation Cephalosporins
- Availability
- Prescription only
- Routes
- Intravenous, Intramuscular
- Markets covered
- 3
- Products on record
- 9
- FDA reports (12 mo)
- 1,121
Overview
Cefepime is an active pharmaceutical ingredient in the Fourth-Generation Cephalosporins group (J01DE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 7 | March 22, 2025 |
| US United States | FDA | 1 | May 10, 2023 |
| EU European Union | EMA | 1 | March 22, 2024 |
CACanada· Health Canada
7 products
Uses
AND CLINICAL USE .................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 5 WARNINGS AND PRECAUTIONS ........................................................................................
5 ADVERSE REACTIONS .......................................................................................................... 9 DRUG INTERACTIONS.........................................................................................................
10 DOSAGE AND ADMINISTRATION .................................................................................... 11 OVERDOSAGE .......................................................................................................................
16 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 16 STORAGE AND STABILITY ................................................................................................ 19 SPECIAL HANDLING INSTRUCTIONS ..............................................................................
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Cefepime for Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: • Pneumonia. 1 ) • Empiric therapy for febrile neutropenic patients.
2 ) • Uncomplicated and complicated urinary tract infections (including pyelonephritis). 3 ) • Uncomplicated skin and skin structure infections. 4 ) • Complicated intra-abdominal infections (used in combination with metronidazole) in adults.
5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
1 Pneumonia Cefepime for Injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species.
EUEuropean Union· EMA
1 product
Uses
1): - Complicated urinary tract infections (cUTI), including pyelonephritis - Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
How to take
Drug interactions
Known interactions involving Cefepime. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 253. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02463997 · revised March 22, 2025
- [2]FDA DailyMed · 02aa374f-37b4-45… · revised May 10, 2023 [PDF]
- [3]European Medicines Agency · EMEA/H/C/005431 · revised March 22, 2024
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.